David A. Ramsay

CIK: 0001283292

Transaction Breakdown

Open Market Buys (P)2 (20.0%)

High conviction signal

Open Market Sales (S)1 (10.0%)

Position reduction

Option Exercises (M)1 (10.0%)

Derivative conversions

Awards (A)5 (50.0%)

Compensation grants

Other (G, F, J, C, D, …)1 (10.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

HALO

HALOZYME THERAPEUTICS, INC.

Officer

SVRA

Savara Inc

Director

Discretionary Trading P&L

Holdings

Transaction History (10 total)

HALO
HALOZYME THERAPEUTICS, INC.
Jul 1, 2026
Award(A)
Restricted Stock Units
Direct
16.2K shares-
HALO
HALOZYME THERAPEUTICS, INC.
Jul 1, 2026
Award(A)
Option to Purchase Common Stock
Direct
39.8K shares-
HALO
HALOZYME THERAPEUTICS, INC.
Jun 30, 2026
Exercise(M)
Direct
10K shares-
HALO
HALOZYME THERAPEUTICS, INC.
Jun 30, 2026
Tax Payment(F)
Direct
5.4K shares at avg. $78.27$423K
HALO
HALOZYME THERAPEUTICS, INC.
Apr 1, 2026
Award(A)
Restricted Stock Units
Direct
10K shares-
SVRA
Savara Inc
Dec 19, 2025
Sale(S)
Direct
20K shares at avg. $6.06$121K
SVRA
Savara Inc
Dec 9, 2025
Award(A)
Direct
40K shares-
SVRA
Savara Inc
Mar 31, 2025
Purchase(P)
Direct
150K shares at avg. $2.77$416K
SVRA
Savara Inc
Dec 12, 2024
Award(A)
Direct
40K shares-
SVRA
Savara Inc
Nov 18, 2024
Purchase(P)
Direct
100K shares at avg. $2.88$288K

		Type	Shares	Price		Ownership
Jul 1, 2026	HALO HALOZYME THERAPEUTICS, INC.	Award(A) Restricted Stock Units	16,232	-	-	Direct
Jul 1, 2026	HALO HALOZYME THERAPEUTICS, INC.	Award(A) Option to Purchase Common Stock	39,823	-	-	Direct
Jun 30, 2026	HALO HALOZYME THERAPEUTICS, INC.	Exercise(M)	10,000	-	$0	Direct
Jun 30, 2026	HALO HALOZYME THERAPEUTICS, INC.	Tax Payment(F)	5,408	$78.27	$423,284	Direct
Apr 1, 2026	HALO HALOZYME THERAPEUTICS, INC.	Award(A) Restricted Stock Units	10,000	-	-	Direct
Dec 19, 2025	SVRA Savara Inc	Sale(S)	20,000	$6.06	$121,220	Direct
Dec 9, 2025	SVRA Savara Inc	Award(A)	40,000	-	-	Direct
Mar 31, 2025	SVRA Savara Inc	Purchase(P)	150,000	$2.77	$416,250	Direct
Dec 12, 2024	SVRA Savara Inc	Award(A)	40,000	-	$0	Direct
Nov 18, 2024	SVRA Savara Inc	Purchase(P)	100,000	$2.88	$287,600	Direct

1-10 of 10 transactions

About RAMSAY DAVID A

RAMSAY DAVID A (SEC CIK 0001283292) files insider reports with the SEC as EVP, PRESIDENT, DRUG DELIVERY of HALOZYME THERAPEUTICS, INC. (HALO) and Director of Savara Inc (SVRA).

Signal8 holds 8 ownership filings by RAMSAY DAVID A (1 Form 3, 7 Form 4), filed between Nov 18, 2024 and Jul 2, 2026. Those filings report 10 transactions, from Nov 18, 2024 to Jul 1, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on RAMSAY DAVID A's filings is in SAN DIEGO, CA.

Recent filings by RAMSAY DAVID A

Jul 1, 2026: Grants or awards of HALO derivative securities (2 lines, Form 4, code A).
Jun 30, 2026: Option exercise of HALO shares (Form 4, code M).
Jun 30, 2026: Tax withholding of HALO shares (Form 4, code F).
Apr 1, 2026: Grant or award of HALO derivative securities (Form 4, code A).
Dec 19, 2025: Open-market sale of SVRA shares (Form 4, code S).

Other insiders filing for HALOZYME THERAPEUTICS, INC. (HALO)

Torley Helen, PRESIDENT AND CEO
Connaughton Bernadette, Director
Daly James M, Director
Posard Matthew L., Director
Appelhans Dannielle, Director
Snellgrove Darren, SVP, Chief Financial Officer

How to read Form 4 transaction codes